NASDAQ$EPIX
Essa Pharma Inc · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Provided a corporate update and reported financial results for the fiscal second quarter.
ESSA Pharma reported its financial results for the fiscal second quarter ended March 31, 2022. The company's cash position is expected to be sufficient to fund current and planned operations through 2024.
- Continued to dose patients in Phase 1 monotherapy study of EPI-7386.
- Expect to present a clinical update on the monotherapy trial in the first half of 2022.
- Several clinical collaborations are underway investigating the potential clinical benefit of EPI-7386 in combination with approved second-generation antiandrogens.
- Company-sponsored Phase 1/2 study of EPI-7386 in combination with enzalutamide in mCRPC patients who have not yet been treated with second-generation antiandrogen therapies.
Headline financials
Revenue & EPS history
Essa Pharma · Revenue · Quarterly
$482K
Forward guidance
ESSA Pharma expects to provide a clinical update on the Phase 1a dose escalation study in the first half of 2022 and believes its cash position is sufficient to fund operations through 2024.
Tailwinds
- Expect to provide a clinical update on the Phase 1a dose escalation study in the first half of 2022.
- The potential clinical benefit of EPI-7386 in combination with approved second-generation antiandrogens.
- The accuracy of ESSA’s financial projections.
- Obtaining positive results of clinical trials.
- Obtaining necessary regulatory approvals.
Headwinds
- Risks and uncertainties related to future events.
- Uncertainties related to ESSA’s ability to control or predict.
- ESSA’s actual results, performance or achievements to be materially different from those expressed or implied.
- Significant medical, scientific, business, economic, competitive, political and social uncertainties and contingencies.
- General business, market and economic conditions.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 10 quarterly earnings reports
-0.3%
Avg return
Earnings day
+1.1%
Avg return
5 days after
-3.2%
Avg return
30 days after
39%
13 / 33 earnings
Positive
+46.0%
Q1 2021
Best reaction
-34.9%
Q3 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | +0.0% | +0.0% | -89.5% | |
| Q2 2025 | +1.2% | -1.8% | -1.2% | |
| Q1 2025 | -3.0% | +3.6% | -2.4% | |
| Q4 2024 | -1.2% | -1.8% | +7.4% | |
| Q3 2024 | -5.5% | -2.6% | +22.9% | |
| Q2 2024 | +4.6% | +4.9% | -21.3% | |
| Q1 2024 | +2.5% | -5.4% | -10.0% | |
| Q4 2023 | +3.2% | +16.4% | +58.7% | |
| Q3 2023 | -2.8% | -4.5% | -5.6% | |
| Q2 2023 | -4.1% | +2.7% | +8.6% | |
| Q1 2023 | +2.1% | +0.3% | -2.4% | |
| Q4 2022 | -6.9% | — | — | |
| Q3 2022 | +3.1% | — | — | |
| Q2 2022 | +5.4% | — | — | |
| Q1 2022 | +1.4% | — | — | |
| Q4 2021 | +0.6% | — | — | |
| Q3 2021 | -34.9% | — | — | |
| Q2 2021 | -1.8% | — | — | |
| Q1 2021 | +46.0% | — | — | |
| Q4 2020 | +8.6% | — | — | |
| Q1 2020 | +0.0% | — | — | |
| Q4 2019 | -0.2% | — | — | |
| Q1 2019 | +3.2% | — | — | |
| Q2 2019 | -8.7% | — | — | |
| Q4 2018 | -2.4% | — | — | |
| Q1 2018 | -8.1% | — | — | |
| Q4 2016 | +0.0% | — | — | |
| Q3 2016 | +0.0% | — | — | |
| Q2 2016 | -5.8% | — | — | |
| Q1 2016 | +2.2% | — | — | |
| Q4 2015 | -8.2% | — | — | |
| Q3 2015 | +0.0% | — | — | |
| Q2 2015 | +0.0% | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro